Instruction for use: Profluzak

Dosage form: capsules

Active substance: Fluoxetine*

ATX

N06AB03 Fluoxetin

Pharmacological groups:

Antidepressant

The nosological classification (ICD-10)

F32 Depressive episode: Adynamic subdepression; Astheno-adynamic subdepressive states; Asthenoadressive disorder; Astheno-depressive disorder; Asthenodepressive state; Astheno-depressive state; Major Depressive Disorder; Vyaloapatichesky depression with retardation; Double Depression; Depressive pseudodement; Depressive illness; Depressive mood disorder; Depressive disorder; Depressive mood disorder; Depressive state; Depressive disorders; Depressive syndrome; Depressive syndrome larviated; Depressive syndrome in psychoses; Depressed masks; Depression; Depression Depletion; Depression with the phenomena of inhibition within the framework of cyclothymia; Depression is smiling; Involutional depression; Involutionary melancholy; Involutional depression; Manic-depressive disorder; Masked Depression; Melancholic Attack; Neurotic depression; Neurotic depression; Shallow Depression; Organic depression; Organic depressive syndrome; Simple depression; Simple melancholic syndrome; Psychogenic depression; Reactive depression; Reactive depression with moderate psychopathological symptoms; Reactive depressive states; Reactive depression; Recurrent depression; Seasonal depressive syndrome; Severostatic depression; Senile Depression; Symptomatic Depression; Somatogenic depression; Cyclotymic depression; Exogenous depression; Endogenous depression; Endogenous Depressive Conditions; Endogenous Depression; Endogenous depressive syndrome

F50.2 Nervous Bulimia: Bulimic Neurosis; Bulimia; Wolf hunger; Kinorexia

Composition and release form

Capsules 1 caps.

fluoxetine 20 mg

in a planar cell pack of 10; in a pack of cardboard 2 packs.

Pharmachologic effect

Pharmacological action - antidepressant.

Selectively blocks the reverse neuronal capture of serotonin and increases its concentration in the synapses of the central nervous system. It is a weak antagonist of cholinergic, adrenergic, histamine receptors.

Pharmacodynamics

Improves mood, reduces feelings of fear and tension, eliminates dysphoria.

Pharmacokinetics

It is well absorbed from the digestive tract. Cmax is achieved 4-8 hours after ingestion. T1 / 2 - 72 hours.

Clinical Pharmacology

A persistent clinical effect develops after 2 weeks of regular admission.

Indications of the drug Profluzak

Depression of various genesis, bulimic neurosis.

Contraindications

Hypersensitivity, atony of the bladder, severe renal dysfunction, glaucoma, prostate adenoma, convulsive syndrome, simultaneous use of MAO inhibitors, epilepsy, pregnancy, breast-feeding.

Application in pregnancy and lactation

Contraindicated. For the duration of treatment, breastfeeding should be discontinued.

Side effects

From the nervous system and sensory organs: headache, nervousness, sleep disturbance, increased anxiety, increased fatigue.

On the part of the intestine: nausea, vomiting, diarrhea, dry mouth, decreased appetite.

Allergic reactions: skin rash, itching, hives, angioedema.

Other: hyponatremia, sensation of fever, weakening of libido.

Interaction

Strengthens the effect of antidiabetic drugs, increases the concentration in the blood.

Dosing and Administration

Inside. Depression: the initial dose is 20 mg once a day in the morning. If necessary, the dose can be increased after 3-4 weeks. The maximum daily dose is 80 mg in 2-3 divided doses.

Bulimic neurosis: 20 mg 3 times a day.

Precautionary measures

Be wary appoint patients with diseases of the cardiovascular system. During the intake, you must exclude the use of alcohol. Profluzak can be used not earlier than 14 days after the abolition of MAO inhibitors.

Storage conditions for Profluzak

In a dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life of Profluzak

capsules 20 mg - 2.5 years.

capsules 20 mg - 4 years.

Do not use after the expiry date printed on the package.